COVID-19-Associated Critical Illness—Report of the First 300 Patients Admitted to Intensive Care Units at a New York City Medical Center

Abstract

Background:

The first confirmed case of novel coronavirus (2019-nCoV) infection in the United States was reported from the state of Washington in January, 2020. By March, 2020, New York City had become the epicenter of the outbreak in the United States.

Methods:

We tracked all patients with confirmed coronavirus-19 (COVID-19) infection admitted to intensive care units (ICU) at Montefiore Medical Center (Bronx, NY). Data were obtained through manual review of electronic medical records. Patients had at least 30 days of follow-up.

Results:

Our first 300 ICU patients were admitted March 10 through April 11, 2020. The majority (60.7%) of patients were men. Acute respiratory distress syndrome (ARDS) was documented in 91.7% of patients; 91.3% required mechanical ventilation. Prone positioning was employed in 58% of patients and neuromuscular blockade in 47.8% of mechanically-ventilated patients. Neither intervention was associated with decreased mortality. Vasopressors were required in 77.7% of patients. Acute kidney injury (AKI) was present on admission in 40.7% of patients, and developed subsequently in 36.0%; 50.9% of patients with AKI received renal replacement therapy (RRT). Overall 30-day mortality rate was 52.3%, and 55.8% among patients receiving mechanical ventilation. In univariate analysis, higher mortality rate was associated with increasing age, male sex, hypertension, obesity, smoking, number of comorbidities, AKI on presentation, and need for vasopressor support. A representative multivariable model for 30-day mortality is also presented, containing patient age, gender, body mass index, and AKI at admission. As of May 11, 2020, 2 patients (0.7%) remained hospitalized.

Conclusions:

Mortality in critical illness associated with COVID-19 is high. The majority of patients develop ARDS requiring mechanical ventilation, vasopressor-dependent shock, and AKI. The variation in mortality rates reported to date likely reflects differences in the severity of illness of the evaluated populations.

Keywords

SARS-CoV-2 COVID-19 novel coronavirus acute respiratory distress syndrome (ARDS)critical illness

Get full access to this article

View all access options for this article.

References

Zhu

Zhang

Wang

, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733.

Holshue

DeBolt

Lindquist

, et al. First case of novel 2019 coronavirus in the United States. N Engl J Med 2020;382:929–936.

Cheng

Luo

Wang

, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838.

Klok

Kruip

MJHA

van der Meer

NJM

, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013

Hendren

Drazner

Bozkurt

, et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020;141(23):1903–1914. doi:10.1161/CIRCULATIONAHA.120.047349

ARDS Definition Task Force, Ranieri

Rubenfeld

, et al. Acute respiratory distress syndrome. The Berlin Definition. JAMA. 2012;307(23):2526–2533.

KDIGO Clinical Practice Guideline for Acute Kidney Injury. AKI definition. Kidney Int Suppl. 2012;2(suppl 1):19–36.

Yang

, et al.

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5

Chen

Cai

, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1–11. doi:10.1001/jamainternmed.2020.0994

10.

Zou

Fang

, et al.

Acute Physiology and Chronic Health Evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019

[published online ahead of print May 1, 2020]. Crit Care Med. 2020;10: 1097/CCM.0000000000004411. doi:10.1097/CCM.0000000000004411

11.

Bhatraju

Ghassemieh

Nichols

, et al. COVID-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012–2022. doi:10.1056/NEJMoa2004500

12.

Wang

Chen

, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430–1434. doi:10.1164/rccm.202003-0736LE

13.

Richardson

Hirsch

Narasimhan

, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775

14.

Cummings

Baldwin

Abrams

, et al. Epidemiology, clinical course and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. doi:10.1016/S0140-6736(20)31189-2

15.

Guerin

Reignier

Richard

, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–2168. doi:10.1056/NEJMoa1214103

16.

Papazian

Aubron

Brochard

, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):69. doi:10.1186/s13613-019-0540-9

17.

Griffiths

MJD

McAuley

Perkins

, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6(1):e000420 . eCollection 2019. doi:10.1136/bmjresp-2019-000420

18.

National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997–2008. doi:10.1056/NEJMoa1901686

19.

Alhazzani

Moller

Arabi

, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020;46(5):854–887. doi:10.1097/CCM.0000000000004363

20.

Ronco

Reis

. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020;16(6):308–310. doi:10.1038/s41581-020-0284-7

21.

Guan

, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032

22.

Hirsch

Ross

, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):P209–P218. https://doi.org/10.1016/j.kint.2020.05.006

23.

Zhou

, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.

24.

Fanelli

Fiorentino

Cantaluppi

, et al. Acute kidney injury in SARS-CoV-2 infected patients. Crit Care. 2020;24(1):155.

25.

Soleimani

. Acute kidney injury in SARS-CoV-2 infection: direct effect of virus on kidney proximal tubule cells. Int J Mol Sci. 2020;21(9):E3275. doi:10.3390/ijms21093275